Biohit Oyj, Total number of voting rights and capital, March 12, 2018 at 1 p.m. (EEST)
A total number of 2,435 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 between 5 December 2017 and 6 February 2018. These shares have been entered into the trade register on March 12, 2018, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of March 13, 2018 together with the existing B-shares.
The share subscription price was EUR 2.2766 per share respectively. The entire subscription price of EUR 5,543.52 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value.
After the subscriptions the number of all Biohit Oyj's shares will rise to 14,889,278 shares and B-shares will rise to 11,913,778 shares.
The share subscription period with stock options I 2013 began on June 1, 2015 and will end May 31, 2019.The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 13, 2011. The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at www.biohithealthcare.com.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com